Diagnostic and therapeutic management of Vogt-Koyanagi-Harada syndrome;Prise en charge diagnostique et thérapeutique du syndrome de Vogt-Koyanagi-Harada

Journal Francais d'Ophtalmologie

Volumn 28, Issue 1, 2005, Pages 9-16

  Touitou, V ^a   Escande, C ^a   Bodaghi, B ^a   Cassoux, N ^a   Wechsler, B ^a   Lemaitre, C ^a   Tran, T H C ^a   Fardeau, C ^a   Piette, J C ^a   LeHoang, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CG angiography; Corticosteroids; Immunosuppressors; Interferon alpha; Lumbar puncture; Serous retinal detachment; Uveitis; Vitiligo

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ADOLESCENT; ADULT; ANGIOGRAPHY; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHOTOMETRY; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

EID: 13844264227     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(05)81020-4     Document Type: Article

References (24)

1. Ramana S, Moorthy, Hajime Inomata, Narsing A. Rao. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol, 1995;39:265-91.
2. Leopold IH. The role of lymphocyte (cell-mediated) immunity in ocular disease. Am J Ophthalmol, 1973;76:619-31.
3. Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease. Curr Eye Res, 2001;22:312-8.
4. Morose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol, 1996;80: 1002-8.
5. Gocho K, Kondo I, Yamaki K, Sakuragi S. Identification of specific antigen for Vogt-Koyanagi-Harada disease: lymphocyte reactivity against the tyrosine family proteins. ARVO abstracts. Invest Ophthalmol Vis Sci, 1999;40:S204.
6. Snyder DA, Tessler HA. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol, 1980;90:69-75.
7. Read RW, Rao NA. Utility of existing Vogt-Koyanagi-Harada syndrome diagnostic criteria at initial evaluation of the individual patient: a retrospective analysis. Ocular Immunol Inflamm, 2000;8: 227-34.
8. Read RW, Holland GN, Rao NA, Tabbara K, Ohno S, Arellanes-Garcia L et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international commitee on nomenclature. Am J Ophthalmol, 2001;131:647-52.
9. Read RW. Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am, 2002;15:333-41.
10. Beniz J, Forster DJ, Lean JS, Smith RE, Rao NA. Variations in clinical features of the Vogt-Koyanagi-Harada syndrome. Retina, 1991;11: 275-80.
11. Kanter PJ, Goldberg MF. Bilateral uveitis with exudative retinal detachment: angiographic appearence. Arch Ophthalmol, 1974; 91:13-9.
12. Herbert CP, Bodaghi B, LeHoang P. Angiographie au vert d'indocyanine au cours des maladies oculaires inflammatoires: principes, interprétation shématique, sémiologie, et intérêt clinique. J. Fr. Ophtalmol, 2001;24:423-47.
13. Herbert CP, LeHoang P, Guex-Crosier Y. Schematic interpretation of lndocyanine green angiography in posterior uveitis, using a standard angiographic protocol. Ophthalmology, 1998;105:432-40.
14. Herbort CP. Posterior uveitis: new insights given by indocyanin green angiography. Eye, 1998;12:757-9.
15. Oshima Y, Harino S, Hara Y, Tano Y. Indocyanin green angiographic findings in Vogt-Koyanagi-Harada disease. Am J Ophthalmol, 1996;122:58-66.
16. Norose K, Yano A, Aosai F, Segawa K. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease. Invest Ohphtalmol Vis Sci, 1990;31:1210-6.
17. Kamondi A, Szegedi A, Papp A, Seres A, Szirmai I. Vogt-Koyanagi-Harada disease presenting initially as aseptic meningoencephalitis. Eur J Neurobiol, 2000;7:719-22.
18. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol, 1991;109:682-7.
19. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE et al. Complications and prognosis factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol, 2001;131:599-606.
20. Kuo IC, Rechdouni A, Rao NA, Johnston RH, Margolis TP, Cunningham ET. Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology, 2000;107:1721-8.
21. Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine, 2001;80:263-70.
22. Hayasaka S, Okabe H, Takahashi J. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol, 1982;218:9-13.
23. Jabs DA, Rosenbaum JT. Letter: guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol, 2001;131:679.
24. Forster DJ, Cano MR, Green RL, Rao NA. Echographic features of the Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol, 1990; 108:1421-6.